Payment overview · 2025
General Payments
$206.36
10 reported records · 9 companies
Healthcare provider profile · identity verified
Raul Zayas, MD
Allopathic & Osteopathic Physicians|Family Medicine · EL PASO, TX · NPI 1942252549
Verified facts
What the public records show
CMS Open Payments records show Raul Zayas, MD received $206.36 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.25 | 18.5% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $24.92 | 12.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.45 | 11.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.34 | 11.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.97 | 10.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.58 | 10.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.69 | 9.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.50 | 9.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.66 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.36 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.25 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
32 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
280 | 75 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
158 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1112 | 355 |
| Levothyroxine Sodium | Levothyroxine Sodium | 522 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 421 | 143 |
| Metformin Hcl | Metformin Hcl | 388 | 132 |
| Lisinopril | Lisinopril | 284 | 95 |
| Farxiga | Dapagliflozin Propanediol | 280 | 75 |
| Metformin Hcl Er | Metformin Hcl | 272 | 95 |
| Losartan Potassium | Losartan Potassium | 265 | 94 |
| Montelukast Sodium | Montelukast Sodium | 227 | 79 |
| Ezetimibe | Ezetimibe | 206 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 65 |
| Ozempic | Semaglutide | 164 | 30 |
| Trulicity | Dulaglutide | 158 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 148 | 51 |
| Carvedilol | Carvedilol | 146 | 49 |
| Gabapentin | Gabapentin | 144 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 53 |
| Alendronate Sodium | Alendronate Sodium | 126 | 48 |
| Omeprazole | Omeprazole | 101 | 41 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 95 | 34 |
| Famotidine | Famotidine | 93 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 28 |
| Simvastatin | Simvastatin | 89 | 33 |
| Ibuprofen | Ibuprofen | 87 | 28 |
| Telmisartan | Telmisartan | 87 | 23 |
| Glipizide | Glipizide | 83 | 28 |
| Vascepa | Icosapent Ethyl | 83 | 26 |
| Sertraline Hcl | Sertraline Hcl | 82 | 29 |
| Alprazolam | Alprazolam | 79 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 76 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 26 |
| Cefuroxime | Cefuroxime Axetil | 72 | 57 |
| Jardiance | Empagliflozin | 72 | 20 |
| Furosemide | Furosemide | 67 | 30 |
| Mounjaro | Tirzepatide | 67 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 27 |
| Prednisone | Prednisone | 64 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 18 |
| Potassium Chloride | Potassium Chloride | 55 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 23 |
| Finasteride | Finasteride | 52 | 16 |
| Glimepiride | Glimepiride | 52 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 17 |
| Januvia | Sitagliptin Phosphate | 51 | 17 |
| Tramadol Hcl | Tramadol Hcl | 51 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Allopurinol | Allopurinol | 48 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 14 |
| Meloxicam | Meloxicam | 48 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 17 |
| Baclofen | Baclofen | 46 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 23 |
| Irbesartan | Irbesartan | 44 | 13 |
| Azithromycin | Azithromycin | 42 | 41 |
| Memantine Hcl | Memantine Hcl | 42 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 19 |
| Spironolactone | Spironolactone | 40 | 13 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Eliquis | Apixaban | 39 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | 15 |
| Trazodone Hcl | Trazodone Hcl | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 19 |
| Levemir Flexpen | Insulin Detemir | 33 | 14 |
| Prolia | Denosumab | 32 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | 11 |
| Ramipril | Ramipril | 30 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 29 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 29 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | 18 |
| Myrbetriq | Mirabegron | 26 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 26 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 15 |
| Alcohol Pads | Alcohol Antiseptic Pads | 23 | 11 |
| Atenolol | Atenolol | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 21 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Cilostazol | Cilostazol | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Sucralfate | Sucralfate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Calcitriol | Calcitriol | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Forteo | Teriparatide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 11 |
| Tradjenta | Linagliptin | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.36 · 10 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, COMIRNATY, CREON, FREESTYLE LIBRE 3, Fluad, Flucelvax, Kerendia, Korlym, MOUNJARO, OTEZLA, PREVNAR 20, REPATHA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error